FY2026 EPS Estimates for Exelixis Increased by Analyst

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Leerink Partnrs increased their FY2026 earnings per share estimates for shares of Exelixis in a report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings per share of $2.56 for the year, up from their prior estimate of $2.54. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

EXEL has been the topic of a number of other reports. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Stifel Nicolaus increased their price objective on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. Citigroup lifted their target price on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Royal Bank of Canada increased their price target on Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th. Finally, Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $41.00 to $33.00 in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Price Performance

EXEL stock opened at $36.70 on Monday. Exelixis has a 12 month low of $20.14 and a 12 month high of $40.02. The firm’s 50-day moving average is $35.71 and its 200 day moving average is $33.32. The company has a market capitalization of $10.27 billion, a PE ratio of 20.73, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bob Oliver sold 18,647 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 140,343 shares of company stock worth $5,177,234. Insiders own 2.85% of the company’s stock.

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. Invesco Ltd. raised its stake in shares of Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Norges Bank purchased a new position in Exelixis during the 4th quarter worth approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec lifted its stake in Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock valued at $82,730,000 after acquiring an additional 1,907,167 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Exelixis by 104.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after acquiring an additional 1,613,482 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Exelixis in the fourth quarter worth $30,321,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.